<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447470</url>
  </required_header>
  <id_info>
    <org_study_id>RXC004/0001</org_study_id>
    <nct_id>NCT03447470</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies</brief_title>
  <official_title>A Modular Multi-Arm, Phase 1, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Anti-cancer Treatments, in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Redx Pharma Plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Redx Pharma Plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of RXC004 as&#xD;
      monotherapy and in combination with Nivolumab in patients with advanced malignancies. In&#xD;
      order to define the doses and schedules for further clinical evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of an ascending monotherapy dose, the doses are pre-defined.&#xD;
&#xD;
      The decision to escalate will be made upon the assessment of safety and tolerability data in&#xD;
      the first cycle of treatment.&#xD;
&#xD;
      Module 1 will commence with a 3+3 dose escalation design up to a recommended Phase 2&#xD;
      monotherapy dose. Patients being monitored for dose limiting toxicities at each dose level.&#xD;
&#xD;
      Characterisation of the PK profile, MTD and/or recommended Phase 2 dose will be defined on&#xD;
      the emerging data&#xD;
&#xD;
      Module 2: RXC004 and Nivolumab - Follows a similar 3+3 dose escalation design using RXC004&#xD;
      plus Nivolumab. The MTD and/or Phase 2 dose will be defined based on the PK profile, emerging&#xD;
      safety and the appearance of any dose limiting toxicities&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation from 0.5mg up to 3mg, the minimum increase in dose will be 0.5mg but larger increases in dose are allowed depending in the observed exposure within a cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Module 1 - Safety and Tolerability of RXC004 by assessment of whether any Dose Limiting Toxicities (DLT) arise from first dose until the end of 21 days of continuous dosing</measure>
    <time_frame>The DLT period will be assessed from the first dose until the end of 21 days of continuous dosing. This will be completed for each dose level until a Maximum Tolerated Dose (MTD) is identified. Estimated time 12 Months in total</time_frame>
    <description>A DLT is defined as an adverse event or abnormal laboratory value. Haematological toxicity of CTCAE grade 4 for more than 4 consecutive days. Grade 3 neutropenia of any duration accompanied by fever &gt;38.5 degrees Celsius. Grage 3 thrombocytopaenia with bleeding. Any other confirmed haematological toxicity &gt;CTCAE grade 4. Non-haematological toxicity &gt;CTCAE grade 3. Any other toxicity that is judged to be a DLT by the Safety Review Committee. An AE resulting in disrupted dosing &gt;14 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Module 2 - Safety and Tolerability of RXC004 in combination with Nivolumab by assessment of whether any Dose Limiting Toxicities (DLT) arise from first dose until the end of 28 days of continuous dosing</measure>
    <time_frame>The DLT period will be assessed from the first dose until the end of 28 days of continuous dosing. This will be completed for each dose level until a Maximum Tolerated Dose (MTD) is identified. Estimated time 12 Months in total</time_frame>
    <description>A DLT is defined as an adverse event or abnormal laboratory value. Haematological toxicity of CTCAE grade 4 for more than 4 consecutive days. Grade 3 neutropenia of any duration accompanied by fever &gt;38.5 degrees Celsius. Grage 3 thrombocytopaenia with bleeding. Any other confirmed haematological toxicity &gt;CTCAE grade 4. Non-haematological toxicity &gt;CTCAE grade 3. Any other toxicity that is judged to be a DLT by the Safety Review Committee. An AE resulting in disrupted dosing &gt;14 days. Any grade 3 or higher immune-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Module 1</measure>
    <time_frame>Throughout the study and at study completion (approximately 1 year)</time_frame>
    <description>Characterise the PK profile of RXC004 following single dose and at steady state and after multiple dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 2</measure>
    <time_frame>Throughout the study and at study completion (approximately 1 year)</time_frame>
    <description>Characterise the PK profile of RXC004 in combination with Nivolumab to following single dose and at steady state and after multiple dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Monotherapy RXC004 - Module 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination RXC004 plus Nivolumab - Module 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given RXC004 at specific doses in combination with a standard dose of Nivolumab and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXC004</intervention_name>
    <description>RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway</description>
    <arm_group_label>Combination RXC004 plus Nivolumab - Module 2</arm_group_label>
    <arm_group_label>Monotherapy RXC004 - Module 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1</description>
    <arm_group_label>Combination RXC004 plus Nivolumab - Module 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        (Summarized due to limitation of characters)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Aged at least 18 years&#xD;
&#xD;
          -  Histological or cytological confirmation of advanced malignancy not considered to be&#xD;
             appropriate for further conventional treatment&#xD;
&#xD;
          -  Patients must use adequate contraception measures for the duration of the study and&#xD;
             for 6 months after the study&#xD;
&#xD;
          -  Patients must have adequate organ functions&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a compound of the same mechanism of action as RXC004&#xD;
&#xD;
          -  No other anti-cancer therapy or investigational product throughout the study&#xD;
&#xD;
          -  Patients with persistent grade 2 or higher diarrhoea&#xD;
&#xD;
          -  Patients at high risk of bone fractures&#xD;
&#xD;
          -  QTc prolongation&#xD;
&#xD;
          -  Known uncontrolled intercurrent illness&#xD;
&#xD;
          -  Known severe allergies to any active or inactive ingredients&#xD;
&#xD;
        In addition for Module 2&#xD;
&#xD;
          -  Patients with any contraindication/hypersensitivity to Nivolumab of excipients&#xD;
&#xD;
          -  Patients with active or prior documented autoimmune of inflammatory disorders within&#xD;
             the past 5 years&#xD;
&#xD;
          -  Patients with active infections, including tuberculosis, hepatitis B, hepatitis C or&#xD;
             human immunodeficiency virus&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases (eg, influenza, varicella) within&#xD;
             4 weeks (28 days) of initiation of study treatment&#xD;
&#xD;
          -  Patients with body weight &lt;40kg&#xD;
&#xD;
          -  Patients with a history of allogeneic organ transplant or active primary&#xD;
             immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Cook</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Jane Robertson CMO</last_name>
    <phone>44(0)1625 469900</phone>
    <email>j.robertson@redxpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Marsden Hospital, Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Juanita Lopez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Debashis Sarker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Natalie Cook</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle</city>
        <zip>NE77DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ruth Plummer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sarah Blagden</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

